University Nantes Hospital
Nantes, 44000, France
NCT Number: NCT05205525
This retro-prospective monocentric observational study compare the impact of the implementation of a restrictive (delayed) versus aggressive (immediate) antibiotic strategy for Ventilator Acquired Pneumonia suspicion without severity symptoms.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nantes, 44000, France
Ventilator acquired pneumonia (VAP) is the leading cause of nosocomial infection in intensive care patients, and has been associated with increased antibiotic consumption, increased morbidity and mortality. VAP diagnosis is difficult due to subjective or non-specific criteria. Delaying antibiotic treatment for VAP suspicion without severity symptoms raises question since the probability of VAP diagnosis, as well as the risk of delaying treatment, is very uncertain. It may nonetheless limit the environmental impact of antibiotic use which is a public health concern. We compared antibiotic sparing and patient outcome, before and after the implementation of a restrictive (delayed) antibiotic strategy versus an aggressive (immediate) antibiotic strategy in VAP suspicion without severity symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
Time frame: 28 days
antibiotic-free days until Day 28 of Intensive Care Units stay
Time frame: 28 days
Mechanical ventilation free days during the first 28 days
Time frame: 28 days
Time frame: 28 days
Time frame: 28 days
Nantes University Hospital
Other
Aggressive Versus Restrictive Initiation of Antimicrobial Treatment in Critically Ill Patients With Suspected Ventilator Acquired Pneumonia Without Severity : a Before and After Observational Study
Acronym: DELAVAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06181669
Bacterial Infections, Bacterial Infections and Mycoses
Detroit, Michigan, United States
View Trial DetailsNCT07255742
Cross Infection, Disease Attributes
Tanta, Egypt
View Trial DetailsNCT05671328
Aspergillosis, Bacterial Infections and Mycoses
Lille, France
View Trial DetailsNCT01948635
Critical Illness, Cross Infection
Lille, Nord, France
View Trial Details